Unit:
Κατεύθυνση Ανάπτυξη Νέων Φαρμάκων: Έρευνα, Κυκλοφορία και ΠρόσβασηLibrary of the School of Health Sciences
Author:
Magiouf Konstantina
Supervisors info:
Κωνσταντίνος Συρίγος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κουρλαμπά Γεωργία, Επίκουρη Καθηγήτρια, Τμήμα Νοσηλευτικής, Πανεπιστήμιο Πελοποννήσου
Φραγκιαδάκη Καλλιόπη, Πανεπιστημιακός Υπότροφος Γ.Ν.Α "ΛΑΪKO"
Original Title:
Οι επιπτώσεις των βιολογικών θεραπειών στον κίνδυνο ανεπιθύμητων καρδιαγγειακών επεισοδίων σε ασθενείς με αγκυλοποιητική σπονδυλίτιδα ή ψωριασική αρθρίτιδα: Μια συστηματική ανασκόπηση της βιβλιογραφίας
Translated title:
Impact of biologic therapies on risk of adverse cardiovascular events in patients with ankylosing spondylitis-AS or psoriatic arthritis-PsA: A systematic literature review.
Summary:
Background: Recent evidence highlights increased mortality and morbidity due to cardiovascular disease, especially within the two major forms of Spondyloarthropathies, Ankylosing Spondylitis and Psoriatic Arthritis. Ηealthcare professionals and patients in these
populations should be alerted regarding the high risk of cardiovascular events and thus,
customize the treatment strategy accordingly.
Objective: This systematic literature review aimed to determine the association between
serious cardiovascular events and biologic therapies in Ankylosing Spondylitis and Psoriatic Arthritis.
Methods: Screening for the study was carried out using PubMed and Scopus databases from the database's inception to the 17th of July 2021. The literature search strategy for
this review is based on the Population, Intervention, Comparator, Outcomes (PICOs)
framework. Randomized controlled trials of biologic therapies for the treatment of Ankylosing Spondylitis and/or Psoriatic Arthritis were included. The primary outcome measure
was the number of serious cardiovascular events reported during the placebo-controlled
phase.
Results: 4,422 articles were generated from keywords, eligibility criteria, and databases.
Following the screening, we retained 13 studies for analysis: 3 in ankylosing spondylitis
and 10 in psoriatic arthritis. Meta-analysis of results was not feasible due to the small
number of the identified studies, the heterogeneity of the biologic treatment and the included populations, and the infrequently reported requested endpoint. According to our
review, no significant change in the short-term risk of major adverse cardiovascular events and significant uncontrolled cerebrocardiovascular events in patients with Ankylosing Spondylitis/Psoriatic Arthritis receiving biological therapy compared with the placebo could be identified.
Conclusion: Further and more extensive trials in Ankylosing Spondylitis/Psoriatic Arthritis patients at high risk of cardiovascular events are needed before firm conclusions can
be drawn.
Main subject category:
Health Sciences
Keywords:
Ankylosing spondylitis, Psoriatic arthritis, Serious cardiovascular events, Biologic therapies.
File:
File access is restricted only to the intranet of UoA.
KM_ΔΙΠΛΩΜΑΤΙΚΗ_FINAL_GR.pdf
1 MB
File access is restricted only to the intranet of UoA.
